Indiana University School Of Medicine
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1903-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.medicine.iu.edu
Clinical Trials
94
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (80 trials with phase data)• Click on a phase to view related trials
Magnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis
- Conditions
- Gastroparesis
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 31
- Registration Number
- NCT04282317
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
Vitamin E for NASH Treatment in HIV Infected Individuals
- Conditions
- NAFLDNASH - Nonalcoholic SteatohepatitisHIV Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 3
- Registration Number
- NCT03669133
- Locations
- 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia
- Conditions
- Intermittent Exotropia
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 8
- Registration Number
- NCT02466659
- Locations
- 🇺🇸
Glick Eye Institute, Indiana University School of Medicine, Indianapolis, Indiana, United States
Effect of Bupivacaine-infused Fibrin Sealant Application on Post-tonsillectomy Pain & Hemorrhage
- Conditions
- Pain, PostoperativePostoperative Hemorrhage
- Interventions
- Biological: Fibrin Sealant
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Indiana University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT02343263
- Locations
- 🇺🇸
Riley Childrens' Hospital, Indianapolis, Indiana, United States
Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:
- Conditions
- Rheumatoid ArthritisOsteoarthritisAvascular Necrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Indiana University School of Medicine
- Registration Number
- NCT02342977
- Locations
- 🇺🇸
Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
Cumberland Pharmaceuticals Reports Positive Phase 2 Results for Ifetroban in Duchenne Muscular Dystrophy Heart Disease
Cumberland Pharmaceuticals' Phase 2 FIGHT DMD trial demonstrated that high-dose ifetroban treatment resulted in a significant 5.4% improvement in left ventricular ejection fraction compared to control groups.
Sleep Disturbances in ICU Patients: New Research Reveals Impact on Recovery and Outcomes
New research presented at ATS 2025 reveals that sleep patterns in ICU patients may serve as important biomarkers for predicting patient outcomes, with atypical N3 sleep linked to longer ICU stays.
Once-Weekly Secnidazole Shows Superior Efficacy for Recurrent Bacterial Vaginosis Treatment
A pilot study of 15 women demonstrated that once-weekly oral secnidazole granules reduced bacterial vaginosis recurrence to 20% over 28 weeks, compared to CDC-recommended treatments with 35-70% recurrence rates.
Lilly's Olumiant Shows Promise in Preserving Beta Cell Function in Type 1 Diabetes
Phase 2 BANDIT trial demonstrates Eli Lilly's Olumiant (baricitinib) can slow progression of type 1 diabetes by preserving insulin-producing beta cell function over 48 weeks of treatment.
GLP-1 Drug Use Surges Among Type 1 Diabetes Patients Despite Safety Concerns
GLP-1 receptor agonist use has increased dramatically among type 1 diabetes patients, with prescriptions rising from 4% to 33% in severely obese adults over the past decade.
RPLND Shows Promise in Early-Stage Seminoma, Reducing Need for Chemo
Retroperitoneal lymph node dissection (RPLND) is emerging as an effective treatment for early-stage II seminoma, potentially reducing reliance on chemotherapy.